S-1 plus oxaliplatin versus S-1 plus cisplatin as first-line treatment for advanced diffuse-type or mixed-type gastric/gastroesophageal junction adenocarcinoma: A randomized, phase 3 trial.

Rui‐Hua Xu(Sun Yat-sen University), Qingfeng Zou(Guangzhou Medical University), Gengsheng Yu(Jiangmen Central Hospital), Xiaobing Chen(Stomatology Hospital), Jianwei Lu(Nantong Tumor Hospital), Lin Shen(Peking University), Yanqiao Zhang(Harbin Medical University), Guo-Long Liu(Guangzhou First People's Hospital), Zhi‐Qiang Wang(Nanjing University of Chinese Medicine), Yunbo Zhao(University of Science and Technology of China), Jianming Xu(Chinese PLA General Hospital), Xia Yuan(Fudan University), Guanghai Dai(Chinese PLA General Hospital), Wei Wang(Qingdao University), Youen Lin(People 's Hospital of Jilin Province), Yanhong Deng(Sun Yat-sen University), Nanfeng Fan(Fujian Medical University), Wangjun Liao(Sun Yat-sen University)
Journal of Clinical Oncology
May 20, 2019
10.1200/jco.2019.37.15_suppl.4017
Cited by 24

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Circular RNA: metabolism, functions and interactions with proteins
|Molecular Cancer|2020|1.6k
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
|The Lancet|2012|1.4k
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
|Journal of Clinical Oncology|2020|1.2k
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k